Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewAmsterdam Pharma Co NVNAMS +1.05%45 Cash Ratio is 8.69 as of Jun. 2026, which is 4% below its 10-year median of 9.06. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,383 Biotechnology companies, NewAmsterdam Pharma Co NV ranks better than 78.45% on this metric.
NewAmsterdam Pharma Co NV has a Cash Ratio of 8.69. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for NewAmsterdam Pharma Co NV's Cash Ratio or its related term are showing as below:
NAMS'
s Cash Ratio Range Over the Past 10 Years
Min: 0.61 Med: 9.06 Max: 20.24
Current: 8.69
During the past 6 years, NewAmsterdam Pharma Co NV's highest Cash Ratio was 20.24. The lowest was 0.61. And the median was 9.06.
NAMS's Cash Ratio is ranked better than 78.45% of 1383
companies
in the Biotechnology industry
Industry Median: 2.93
vs NAMS: 8.69
NewAmsterdam Pharma Co NV (NAS:NAMS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
NewAmsterdam Pharma Co NV Cash Ratio Related Terms
NewAmsterdam Pharma Co NV Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Cash Ratio distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV (NAMS) has a Cash Ratio of 8.69 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on NewAmsterdam Pharma Co NV and its competitors. This is near median its historical median of 9.06. Over the past decade, NewAmsterdam Pharma Co NV's Cash Ratio has ranged from 0.61 to 20.24. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #298 out of 1383 companies in the Biotechnology industry, placing it in the top 21.5%.
Is NewAmsterdam Pharma Co NV's Cash Ratio too high?
NewAmsterdam Pharma Co NV's current Cash Ratio of 8.69 is near median its 10-year median of 9.06. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 20.24. The Biotechnology industry median Cash Ratio is 2.93. NewAmsterdam Pharma Co NV's value of 8.69 is 196.6% above this industry median. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #298 out of 1383 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Cash Ratio compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #298 out of 1383 companies for Cash Ratio. This places NewAmsterdam Pharma Co NV in the top 22% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. NewAmsterdam Pharma Co NV's value of 8.69 is 196.6% above this benchmark. Historically, NewAmsterdam Pharma Co NV's own Cash Ratio has ranged from 0.61 to 20.24 over the past decade. While the company's 10-year median is 9.06 vs. the industry median of 2.93, NewAmsterdam Pharma Co NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewAmsterdam Pharma Co NV's current Cash Ratio of 8.69 is 196.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on NewAmsterdam Pharma Co NV and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current Cash Ratio is 8.69, which is near median its own 10-year median of 9.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Cash Ratio is 8.69, which is near median its 10-year median of 9.06 and 196.6% above the Biotechnology industry median of 2.93. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Cash Ratio is 8.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
Cash Ratio: 8.69 (near median its 10-year median of 9.06)
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
Industry Position: 196.6% above the Biotechnology median (#298 of 1383)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
